Influence of Inflammation and Atherosclerosis in Atrial Fibrillation

Current Atherosclerosis Reports

Volumn 19, Issue 1, 2017, Pages

  da Silva, Rose Mary Ferreira Lisboa ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Atherosclerosis; Atrial fibrillation; Cardiovascular disease; Inflammation; Lipid profile; Thrombogenesis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTICOAGULANT AGENT; C REACTIVE PROTEIN; CARBOHYDRATE BINDING PROTEIN; GALECTIN 3; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NATRIURETIC FACTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR NECROSIS FACTOR;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; ATRIAL FIBRILLATION; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CARDIOVERSION; CELL DEATH; CEREBROVASCULAR ACCIDENT; CHEMOTAXIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; EMBOLISM; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART MUSCLE NECROSIS; HUMAN; HYPERTENSION; INCIDENCE; INFLAMMATION; INFLAMMATORY DISEASE; LEUKOCYTE MIGRATION; MACROPHAGE; METABOLIC SYNDROME X; MORTALITY; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PHAGOCYTOSIS; RECURRENT DISEASE; REVIEW; RISK FACTOR; SEDENTARY LIFESTYLE; ANIMAL; COMPLICATION; LIPID METABOLISM; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANIMALS; ATHEROSCLEROSIS; ATRIAL FIBRILLATION; HUMANS; INFLAMMATION; LIPID METABOLISM; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 85009952131     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-017-0639-0     Document Type: Review

References (52)

1. •• Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–95. doi:10.1056/NEJMra043430. This article explains the pathophysiology of atherosclerosis and its link with inflammation. Several different inflammatory markers, with different biological activities, contribute to the risk of coronary artery disease.
2. Rein P, Saely CH, Silbernagel G, Vonbank A, Mathies R, Drexel H, et al. Systemic inflammation is higher in peripheral artery disease than in stable coronary artery disease. Atherosclerosis. 2015;239(2):299–303. doi:10.1016/j.atherosclerosis.2015.01.021.
3. Akboga MK, Canpolat U, Yayla C, Ozcan F, Ozeke O, Topaloglu S, et al. Association of platelet to lymphocyte ratio with inflammation and severity of coronary atherosclerosis in patients with stable coronary artery disease. Angiology. 2016;67(1):89–95. doi:10.1177/0003319715583186.
4. Cimato TR. Persistent stem cell-driven inflammation in patients with prior MI and stroke. Eur Heart J. 2016. doi:10.1093/eurheartj/ehw323.
5. Kinoshita T, Asai T, Takashima N, Hosoba S, Suzuki T, Kambara A, et al. Preoperative C-reactive protein and atrial fibrillation after off-pump coronary bypass surgery. Eur J Cardiothorac Surg. 2011;40(6):1298–303. doi:10.1016/j.ejcts.2011.03.027.
6. Yo CH, Lee SH, Chang SS, Lee MC, Lee CC. Value of high-sensitivity C-reactive protein assays in predicting atrial fibrillation recurrence: a systematic review and meta-analysis. BMJ Open. 2014;4(2), e004418. doi:10.1136/bmjopen-2013-004418.
7. • Jiang H, Wang W, Wang C, Xie X, Hou Y. Association of pre-ablation level of potential blood markers with atrial fibrillation recurrence after catheter ablation: a meta-analysis. Europace. 2016. doi:10.1093/europace/euw088. This is a meta-analysis showed that the association between recurrence of atrial fibrillation after ablation in patients with increased levels of atrial natriuretic peptide, brain natriuretic peptide, N-terminal pro-brain natriuretic peptide, interleukin-6, C-reactive protein, low density lipoprotein, and tissue inhibitor of metal loproteinase-2.
8. • Hijazi Z, Oldgren J, Siegbahn A, Granger CB, Wallentin L. Biomarkers in atrial fibrillation: a clinical review. Eur Heart J. 2013;34(20):1475–80. doi:10.1093/eurheartj/eht024. This is a review about the cardiac biomarkers and their use in risk stratification of patients with atrial fibrillation.
9. Troughton RW, Crozier I. Fine tuning risk stratification for atrial fibrillation. J Am Coll Cardiol. 2013;61(22):2285–7. doi:10.1016/j.jacc.2013.02.066.
10. • Aulin J, Siegbahn A, Hijazi Z, Ezekowitz MD, Andersson U, Connolly SJ, et al. Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation. Am Heart J. 2015;170(6):1151–60. doi:10.1016/j.ahj.2015.09.018. In patients from the RE-LY study, interleukin-6 was associated with increased risk of stroke, major bleeding, vascular death, and the composite of thromboembolic events independent of clinical risk factors.
11. • Hijazi Z, Aulin J, Andersson U, Alexander JH, Gersh B, Granger CB, et al. Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. Heart. 2016;102(7):508–17. doi:10.1136/heartjnl-2015-308887. Among the 18,201 patients in the ARISTOTLE study on anticoagulation, interleukin-6 and C-reactive protein were associated with increased risk of death.
12. Wallentin L, Hijazi Z, Andersson U, Alexander JH, De Caterina R, Hanna M, et al. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation. 2014;130(21):1847–58. doi:10.1161/CIRCULATIONAHA.
13. • January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland Jr JC, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1–76. doi:10.1016/j.jacc.2014.03.022. This is one of the guidelines on atrial fibrillation, with epidemiological data, classification, pathophysiology and management of patients with this arrhythmia.
14. • Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics—2016 Update: a report from the American Heart Association. Circulation. 2016;133(4):e38-360. doi:10.1161/CIR.0000000000000350. This article is published annually by the American Heart Association with updated epidemiological data of cardiovascular diseases.
15. •• Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473(7347):317–25. doi:10.1038/nature10146. It is an important article on the developmental stages of atherosclerosis, the role of inflammation and the biomarkers, with animal experiments and human studies.
16. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32(9):2045–51. doi:10.1161/ATVBAHA.108.179705.
17. Wong BW, Meredith A, Lin D, McManus BM. The biological role of inflammation in atherosclerosis. Can J Cardiol. 2012;28(6):631–41. doi:10.1016/j.cjca.2012.06.023.
18. Hovland A, Jonasson L, Garred P, Yndestad A, Aukrust P, Lappegård KT, et al. The complement system and toll-like receptors as integrated players in the pathophysiology of atherosclerosis. Atherosclerosis. 2015;241(2):480–94. doi:10.1016/j.atherosclerosis.2015.05.038.
19. Libby P, Lichtman AH, Hansson GK. Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity. 2013;38(6):1092–104. doi:10.1016/j.immuni.2013.06.009.
20. Libby P, Bornfeldt KE, Tall AR. Atherosclerosis: successes, surprises, and future challenges. Circ Res. 2016;118(4):531–4. doi:10.1161/CIRCRESAHA.116.308334.
21. •• Guo Y, Lip GY, Apostolakis S. Inflammation in atrial fibrillation. J Am Coll Cardiol. 2012;60(22):2263–70. doi:10.1016/j.jacc.2012.04.063. This is a review article on markers of inflammation and atrial fibrillation, with a description of each marker and their effects.
22. •• Hu YF, Chen YJ, Lin YJ, Chen SA. Inflammation and the pathogenesis of atrial fibrillation. Nat Rev Cardiol. 2015;12(4):230–43. doi:10.1038/nrcardio.2015.2. This article discusses the inflammatory pathways (risk factors, cytokines, immune factors), which are involved in the pathophysiology of atrial fibrillation.
23. Strissel KJ, Denis GV, Nikolajczyk BS. Immune regulators of inflammation in obesity-associated type 2 diabetes and coronary artery disease. Curr Opin Endocrinol Diabetes Obes. 2014;21(5):330–8. doi:10.1097/MED.0000000000000085.
24. • Domingueti CP, Dusse LM, Carvalho M, de Sousa LP, Gomes KB, Fernandes AP. Diabetes mellitus: the linkage between oxidative stress, inflammation, hypercoagulability and vascular complications. J Diabetes Complications. 2016;30(4):738–45. doi:10.1016/j.jdiacomp.2015.12.018. This is a review article about the connection between inflammation, endothelial dysfunction and hypercoagulable state in patients with diabetes mellitus and its vascular complications.
25. • Seccia TM, Caroccia B, Muiesan ML, Rossi GP. Atrial fibrillation and arterial hypertension: a common duet with dangerous consequences where the renin angiotensin-aldosterone system plays an important role. Int J Cardiol. 2016;206:71–6. doi:10.1016/j.ijcard.2016.01.007. This article discusses the frequency of atrial fibrillation in patients with hypertension, the role of the renin-angiotensin-aldosterone system in the induction of fibrosis and cardiac remodeling and the role of aldosterone in the development of arrhythmia.
26. Idris-Khodja N, Mian MO, Paradis P, Schiffrin EL. Dual opposing roles of adaptive immunity in hypertension. Eur Heart J. 2014;35(19):1238–44. doi:10.1093/eurheartj/ehu119.
27. Hajhosseiny R, Matthews GK, Lip GY. Metabolic syndrome, atrial fibrillation, and stroke: tackling an emerging epidemic. Heart Rhythm. 2015;12(11):2332–43. doi:10.1016/j.hrthm.2015.06.038.
28. • Santhanakrishnan R, Wang N, Larson MG, Magnani JW, McManus DD, Lubitz SA, et al. Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation. 2016;133(5):484–92. doi:10.1161/CIRCULATIONAHA.115.018614. This is the Framingham Heart Study between 1980 and 2012 showing the relationship between atrial fibrillation and heart failure.
29. Chaikriangkrai K, Valderrabano M, Bala SK, Alchalabi S, Graviss EA, Nabi F, et al. Prevalence and implications of subclinical coronary artery disease in patients with atrial fibrillation. Am J Cardiol. 2015;116(8):1219–23. doi:10.1016/j.amjcard.2015.07.041.
30. Stellos K, Rahmann A, Kilias A, Ruf M, Sopova K, Stamatelopoulos K, et al. Expression of platelet-bound stromal cell-derived factor-1 in patients with non-valvular atrial fibrillation and ischemic heart disease. J Thromb Haemost. 2012;10(1):49–55. doi:10.1111/j.1538-7836.2011.04547.
31. • Soliman EZ, Lopez F, O’Neal WT, Chen LY, Bengtson L, Zhang ZM, et al. Atrial fibrillation and risk of ST-segment-elevation versus non-ST-segment-elevation myocardial infarction: The Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2015;131(21):1843–50. doi:10.1161/CIRCULATIONAHA.114.014145. This is a study that evaluated the association between atrial fibrillation and incident myocardial infarction in 14,462 participants without baseline coronary artery disease.
32. Proietti M, Calvieri C, Malatino L, Signorelli S, Corazza GR, Perticone F, et al. Relationship between carotid intima-media thickness and non valvular atrial fibrillation type. Atherosclerosis. 2015;238(2):350–5. doi:10.1016/j.atherosclerosis.2014.12.022.
33. O’Neal WT, Efird JT, Qureshi WT, Yeboah J, Alonso A, Heckbert SR, Nazarian S, Soliman EZ. Coronary Artery calcium progression and atrial fibrillation: The multi-ethnic study of atherosclerosis. Circ Cardiovasc Imaging. 2015; 8(12). doi: 10.1161/CIRCIMAGING.115.003786.
34. O’Neal WT, Efird JT, Nazarian S, Alonso A, Heckbert SR, Soliman EZ. Peripheral arterial disease and risk of atrial fibrillation and stroke: the multi-ethnic study of atherosclerosis. J Am Heart Assoc. 2014;3(6), e001270. doi:10.1161/JAHA.114.001270.
35. • Norby FL, Soliman EZ, Chen LY, Bengtson LG, Loehr LR, Agarwal SK, et al. Trajectories of cardiovascular risk factors and incidence of atrial fibrillation over a 25-year follow-up: The ARIC Study (Atherosclerosis Risk in Communities). Circulation. 2016;134(8):599–610. doi:10.1161/CIRCULATIONAHA.115.020090. This is a case–control study showing that patients who developed atrial fibrillation have increased cardiovascular risk factors many years before the diagnosis of arrhythmia.
36. •• Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC endorsed by the European Stroke Organisation (ESO). Eur Heart J. 2016. doi:10.1093/eurheartj/ehw210. It is the last published guideline on atrial fibrillation, with epidemiological data, classification, pathophysiology, and management of patients with this arrhythmia.
37. Tamariz L, Hernandez F, Bush A, Palacio A, Hare JM. Association between serum uric acid and atrial fibrillation: a systematic review and meta-analysis. Heart Rhythm. 2014;11(7):1102–8. doi:10.1016/j.hrthm.2014.04.003.
38. Guo Y, Lip GY, Apostolakis S. Inflammatory biomarkers and atrial fibrillation: potential role of inflammatory pathways in the pathogenesis of atrial fibrillation-induced thromboembolism. Curr Vasc Pharmacol. 2015;13(2):192–201. doi:10.2174/15701611113116660165.
39. Madrigal‐Matute J, Lindholt JS, Fernandez‐Garcia CE, Benito‐Martin A, Burillo E, Zalba G, et al. Galectin‐3, a biomarker linking oxidative stress and inflammation with the clinical outcomes of patients with atherothrombosis. J Am Heart Assoc. 2014;3(4), e000785. doi:10.1161/JAHA.114.000785.
40. Wu XY, Li SN, Wen SN, Nie JG, Deng WN, Bai R, et al. Plasma galectin-3 predicts clinical outcomes after catheter ablation in persistent atrial fibrillation patients without structural heart disease. Europace. 2015;17(10):1541–7. doi:10.1093/europace/euv045.
41. •• Wang MX, Deng XL, Mu BY, Cheng YJ, Chen YJ, Wang Q, et al. Effect of colchicine in prevention of pericardial effusion and atrial fibrillation: a meta-analysis. Intern Emerg Med. 2016;11(6):867–76. doi:10.1007/s11739-016-1496-5. This is a meta-analysis of randomized controlled studies which demonstrated that colchicine not significantly decreased the risk of pericardial effusion and atrial fibrillation in the postoperative period.
42. Viviano A, Kanagasabay R, Zakkar M. Is perioperative corticosteroid administration associated with a reduced incidence of postoperative atrial fibrillation in adult cardiac surgery? Interact Cardiovasc Thorac Surg. 2014;18(2):225–9. doi:10.1093/icvts/ivt486.
43. Zakkar M, Ascione R, James AF, Angelini GD, Suleiman MS. Inflammation, oxidative stress and postoperative atrial fibrillation in cardiac surgery. Pharmacol Ther. 2015;154:13–20. doi:10.1016/j.pharmthera.2015.06.009.
44. Patti G.,Bennett R.,Seshasai S.R.K.,Cannon C.P.,Cavallari I.,Chello M.,Nusca A.,Mega S.,Caorsi C.,Spadaccio C.,Keun On Y.,Mannacio V.,Berkan O.,Yilmaz M.B.,Katrancioglu N.,Ji Q.,Kourliouros A.,Baran C.,Pasceri V.,Akar A.R.,Kaski J.C.,Di Sciascio G.,Ray K.K.Statin pretreatment and risk of in-hospital atrial fibrillation among patients undergoing cardiac surgery: A collaborative meta-analysis of 11 randomized controlled trials.Europace 17(6),2015, pp:855-863.
45. Veronese G, Montomoli J, Schmidt M, Horváth-Puhó E, Sørensen HT. Statin use and risk of atrial fibrillation or flutter: a population-based case-control Study. Am J Ther. 2015;22(3):186–94. doi:10.1097/MJT.0b013e31827ab488.
46. Hsieh YC, Hung CY, Li CH, Liao YC, Huang JL, Lin CH, et al. Angiotensin-receptor blocker, angiotensin-converting enzyme inhibitor, and risks of atrial fibrillation: a nationwide cohort study. Medicine (Baltimore). 2016;95(20), e3721. doi:10.1097/MD.0000000000003721.
47. Mohanty S, Mohanty P, Trivedi C, Gianni C, Bai R, Burkhardt JD, et al. Association of pretreatment with angiotensin-converting enzyme inhibitors with improvement in ablation outcome in atrial fibrillation patients with low left ventricular ejection fraction. Heart Rhythm. 2015;12(9):1963–71. doi:10.1016/j.hrthm.2015.06.007.
48. Hijazi Z, Lindbäck J, Alexander JH, Hanna M, Held C, Hylek EM, et al. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J. 2016;37(20):1582–90. doi:10.1093/eurheartj/ehw054.
49. Oldgren J, Hijazi Z, Lindbäck J, Alexander JH, Connolly SJ, Eikelboom JW, et al. Performance and validation of a novel biomarker-based stroke risk score for atrial fibrillation. Circulation. 2016. doi:10.1161/CIRCULATIONAHA.116.022802.
50. Kirchhof P, Breithardt G, Aliot E, Al Khatib S, Apostolakis S, Auricchio A, et al. Personalized management of atrial fibrillation: proceedings from the fourth atrial fibrillation competence NETwork/European Heart Rhythm Association consensus conference. Europace. 2013;15(11):1540–56. doi:10.1093/europace/eut232.
51. Pierri MD, Crescenzi G, Zingaro C, D’Alfonso A, Capestro F, Scocco V, et al. Prevention of atrial fibrillation and inflammatory response after on-pump coronary artery bypass using different statin dosages: a randomized, controlled trial. Gen Thorac Cardiovasc Surg. 2016;64(7):395–402. doi:10.1007/s11748-016-0647-y.
52. Heijman J, Algalarrondo V, Voigt N, Melka J, Wehrens XH, Dobrev D, et al. The value of basic research insights into atrial fibrillation mechanisms as a guide to therapeutic innovation: a critical analysis. Cardiovasc Res. 2016;109(4):467–79. doi:10.1093/cvr/cvv275.